Jacobi Capital Management LLC boosted its position in Novartis AG (NYSE:NVS – Get Rating) by 7.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,429 shares of the company’s stock after buying an additional 359 shares during the quarter. Jacobi Capital Management LLC’s holdings in Novartis were worth $476,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently bought and sold shares of NVS. Optimum Investment Advisors grew its holdings in shares of Novartis by 10.9% during the first quarter. Optimum Investment Advisors now owns 1,126 shares of the company’s stock valued at $99,000 after purchasing an additional 111 shares during the last quarter. Hanson & Doremus Investment Management boosted its position in shares of Novartis by 13.4% during the first quarter. Hanson & Doremus Investment Management now owns 972 shares of the company’s stock worth $85,000 after buying an additional 115 shares during the period. Harbor Investment Advisory LLC boosted its position in shares of Novartis by 6.7% during the first quarter. Harbor Investment Advisory LLC now owns 1,935 shares of the company’s stock worth $170,000 after buying an additional 122 shares during the period. Capital Investment Advisory Services LLC boosted its position in shares of Novartis by 2.8% during the first quarter. Capital Investment Advisory Services LLC now owns 4,596 shares of the company’s stock worth $403,000 after buying an additional 126 shares during the period. Finally, Mission Wealth Management LP boosted its position in shares of Novartis by 1.7% during the fourth quarter. Mission Wealth Management LP now owns 7,520 shares of the company’s stock worth $658,000 after buying an additional 128 shares during the period. 9.40% of the stock is owned by institutional investors.
Novartis Price Performance
Shares of NYSE:NVS opened at $85.57 on Friday. The company’s fifty day moving average is $85.04 and its two-hundred day moving average is $86.61. The company has a quick ratio of 1.13, a current ratio of 1.38 and a debt-to-equity ratio of 0.35. Novartis AG has a 12-month low of $79.09 and a 12-month high of $95.17. The company has a market cap of $189.33 billion, a P/E ratio of 8.36, a price-to-earnings-growth ratio of 2.41 and a beta of 0.51.
Analyst Upgrades and Downgrades
NVS has been the subject of several analyst reports. Barclays boosted their price objective on Novartis from CHF 80 to CHF 85 in a research report on Thursday, April 14th. upgraded Novartis from a “hold” rating to a “buy” rating in a research report on Thursday, April 14th. Morgan Stanley upped their target price on Novartis from CHF 90 to CHF 94 in a research report on Friday, May 6th. Wolfe Research downgraded Novartis from an “outperform” rating to a “market perform” rating in a research report on Monday, May 9th. Finally, Oppenheimer downgraded Novartis from an “outperform” rating to a “market perform” rating in a research report on Friday, June 3rd. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $87.33.
Novartis Company Profile
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.
- Get a free copy of the StockNews.com research report on Novartis (NVS)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.